Wednesday, July 8, 2026

Patent intelligence · US

US 8742131

7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof

granted A61KA61K31/407A61K31/4188A61K45/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 8
Applicant portfolio 46
Patent details — US 8742131
Jurisdiction
US
Status
granted
Grant date
Jun 3, 2014
Expiration
May 29, 2034
Claims
14
CPC classes
A61K, A61K31/407, A61K31/4188, A61K45/06
View on Google Patents ↗

Quick answer

US 8742131 (7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof) is held by THERON PHARMACEUTICALS, INC.. Status: granted. Granted Jun 3, 2014. Expires May 29, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K31/407, A61K31/4188, A61K45/06, A61K9/0078, A61P

More from THERON PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12318376

    Compositions of a polyorthoester and an aprotic solvent

    Heron Therapeutics, Inc. · Expires May 29, 2045

    granted
  2. US 12290520

    Methods of use of emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Expires May 1, 2045

    granted
  3. US 12115254

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Expires Oct 10, 2044

    granted
  4. US 12115255

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Expires Oct 10, 2044

    granted
  5. US 11878074

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Expires Jan 18, 2044

    granted
  6. US 11844837

    Compositions of a polyorthoester and an organic acid excipient

    Heron Therapeutics, Inc. · Expires Dec 14, 2043

    granted
  7. US 11744800

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Expires Aug 31, 2043

    granted
  8. US 11413350

    Long-acting polymeric delivery systems

    Heron Therapeutics, Inc. · Expires Aug 11, 2042

    granted

Frequently asked questions

What is US patent 8742131?

US 8742131 (7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof) is held by THERON PHARMACEUTICALS, INC.. Status: granted. Granted Jun 3, 2014. Expires May 29, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8742131?

THERON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 46 pharmaceutical patents for this assignee.

When does US 8742131 expire?

Our index shows an expiration date of May 29, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.